Bibliographic Details
| Title: |
A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study. |
| Authors: |
T. Krishnareddy, Naveen1, Thomas, Jestin V.2, Nair, Saritha S.3, N. Mulakal, Johannah3, Maliakel, Balu P.3, Krishnakumar, I. M.3 |
| Source: |
BioMed Research International. 9/23/2018, Vol. 2018, p1-10. 10p. |
| Subject Terms: |
*LIVER physiology, *PEOPLE with alcoholism, *AMINOTRANSFERASES, *BIOMARKERS, *C-reactive protein, *DRUG delivery systems, *GLUTATHIONE, *GLYCOSIDES, *INFLAMMATORY mediators, *INTERLEUKINS, *SUPEROXIDE dismutase, *OXIDATIVE stress, *RANDOMIZED controlled trials, *BLIND experiment, *CURCUMIN, *GAMMA-glutamyltransferase, *PHARMACODYNAMICS |
| Abstract: |
Considering the recent interest in free (unconjugated) curcuminoids delivery, the present study investigated the efficacy of a novel food-grade free-curcuminoids delivery system (curcumin-galactomannoside complex; CGM) in improving the hepatic function markers (inflammation and oxidative stress) in chronic alcoholics. The double-blinded, placebo-controlled study randomized 48 subjects with elevated serum transaminases and gamma-glutamyl transferase (GGT) levels, who were allocated to two groups (n=24) and to receive either placebo or CGM at (250 mg × 2)/day for 8 weeks. While liver function markers (transaminases and GGT) in the placebo group showed an increase (~ 9.5%), CGM group indicated a significant decrease in transaminases (31%) and GGT (29%) from the baseline levels. The beneficial effect of CGM was also clear from the significant increase (p <0.001) in endogenous antioxidants (GSH, SOD, and GPx) and decrease in inflammatory markers (IL-6 and CRP) levels (p <0.001) as compared to both the baseline and placebo group. To summarize, the nutritional intervention of CGM-curcumin was found to offer a significant hepatoprotective effect to attenuate the alcohol induced alterations to hepatic function markers. The Indian Medical Council and Drug Controller General of India approved Clinical Trial Registry No. CTRI/2018/03/012385. [ABSTRACT FROM AUTHOR] |
|
Copyright of BioMed Research International is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
